Parathyroid hormone prodrug - Ascendis Pharma

Drug Profile

Parathyroid hormone prodrug - Ascendis Pharma

Alternative Names: ACP 014; TransCon parathyroid hormone; TransCon PTH

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ascendis Pharma
  • Class
  • Mechanism of Action Parathyroid hormone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypoparathyroidism

Most Recent Events

  • 26 Sep 2017 Phase-I clinical trials in Hypoparathyroidism in Australia (SC) (ACTRN12617001375347)
  • 01 Apr 2017 Pharmacokinetics data from a preclinical trial in Hypoparathyroidism presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top